Klaus H. Metzeler

Jan 6, 2024 | nature.com | Anne Sophie Kubasch |Song Wang |Sebastian Schwind |Klaus H. Metzeler |Madlen Jentzsch |Kristin Reiche | +2 more

AbstractB-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited.

Oct 25, 2023 | nature.com | Klaus H. Metzeler |Georg-Nikolaus Franke |Vladan Vucinic |Uwe Platzbecker

To the Editor:Some of the gene mutations detected during the development of myeloid neoplasm are also frequently found in elderly individuals without diagnosed hematologic malignancy and here referred to as clonal hematopoiesis (CH) of indeterminate potential (CHIP) [1]. CHIP associates with an elevated risk of developing a myeloid neoplasm [1], as compared to non-CHIP conductors [1].